Occult well differentiated thyroid carcinoma presenting as cervical node disease
- PMID: 7676714
- DOI: 10.1007/BF00294746
Occult well differentiated thyroid carcinoma presenting as cervical node disease
Abstract
Records of 92 patients with differentiated thyroid carcinoma presenting as cervical adenopathy without a palpable mass were reviewed to identify prognostic factors and to evaluate therapy. Patients were treated between 1940 and 1990 and were observed for 3 to 48 years (median 18 years). Follow-up data were obtained by chart review, correspondence, and telephone contact. Among the group, 20 patients had unilateral and 72 bilateral thyroid lobectomy, with node dissection in 77. Thyroid hormone was used in 50 patients and radioactive iodine in 20. Patients were younger than the overall population of patients with differentiated thyroid carcinoma, with more men and more multifocal thyroid disease. Risk group defined by age and sex was the most important determinant of survival. All women 50 years of age or younger and all men 40 or younger (low risk group) survived independent of the type of initial operation or use of thyroid-stimulating hormone suppression or radioactive iodine. Of the low-risk patients, 16% had recurrent disease but were treated successfully with surgery or radioactive iodine; 28% of the older patients (high risk) died of disease. A trend for better survival was noted in high risk patients undergoing bilateral thyroidectomy and in patients receiving thyroid suppression. Of the high risk patients, 26% had recurrent disease, with a 71% mortality rate. Age and sex are the primary determinants of survival. Therapy should be based on risk factors. Low risk patients should have conservative thyroid surgery and modified or limited node dissection.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.J Clin Endocrinol Metab. 1997 Nov;82(11):3553-62. doi: 10.1210/jcem.82.11.4373. J Clin Endocrinol Metab. 1997. PMID: 9360506
-
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.Am J Med. 1994 Nov;97(5):418-28. doi: 10.1016/0002-9343(94)90321-2. Am J Med. 1994. PMID: 7977430 Clinical Trial.
-
Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.Ann Ital Chir. 2006 Mar-Apr;77(2):107-13. Ann Ital Chir. 2006. PMID: 17147082
-
Carcinoma of the thyroid in children--a review.J Pediatr Endocrinol Metab. 1997 Nov-Dec;10(6):561-8. doi: 10.1515/jpem.1997.10.6.561. J Pediatr Endocrinol Metab. 1997. PMID: 9467125 Review.
-
An overview of the management of papillary and follicular thyroid carcinoma.Thyroid. 1999 May;9(5):421-7. doi: 10.1089/thy.1999.9.421. Thyroid. 1999. PMID: 10365671 Review.
Cited by
-
Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes.World J Surg. 2010 Jun;34(6):1222-31. doi: 10.1007/s00268-009-0359-x. World J Surg. 2010. PMID: 20066418 Clinical Trial.
-
Papillary microcarcinoma.World J Surg. 2008 May;32(5):747-53. doi: 10.1007/s00268-007-9453-0. World J Surg. 2008. PMID: 18264828 Free PMC article.
-
Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time-Dependent Changes in Calcification and Vascularity During Active Surveillance.World J Surg. 2016 Mar;40(3):529-37. doi: 10.1007/s00268-015-3349-1. World J Surg. 2016. PMID: 26581368
-
Incidentally discovered papillary carcinoma of the thyroid: value of ultrasonographic follow-up. A case-report.J Endocrinol Invest. 2000 Apr;23(4):251-4. doi: 10.1007/BF03343717. J Endocrinol Invest. 2000. PMID: 10853712
-
Occult papillary thyroid carcinoma: diagnostic and clinical implications in the era of routine ultrasonography.World J Surg. 2008 Sep;32(9):1955-60. doi: 10.1007/s00268-008-9614-9. World J Surg. 2008. PMID: 18594906
References
MeSH terms
LinkOut - more resources
Medical